



# Poster Presentations

THURSDAY, APRIL 16 | 5:15-6:15P - TWO 30-MINUTES SESSION

SCREEN / TIME

Impact of belantamab mafodotin-Containing Regimens on Renal Function in Patients With Relapsed/Refractory Multiple Myeloma and Mild/Moderate Renal Impairment in the DREAMM-7 and DREAMM-8 Trials

5:15-5:45P

1

Deep Responses and Durable Outcomes in Patients Treated With belantamab mafodotin Plus pomalidomide and dexamethasone From Long-Term Follow-Up of the Phase 3 DREAMM-8 Study

5:45-6:15P

Impact of New or Worsening Anemia and Thrombocytopenia on Clinical Outcomes in JAK Inhibitor-Naive Myelofibrosis Patients Treated With ruxolitinib

5:15-5:45P

2

Patients With Relapsed/Refractory Multiple Myeloma Who Achieved Sustained Minimal Residual Disease Negativity in the DREAMM-7 Trial

5:45-6:15P

Development of Ambulatory Oncology Clinical Pharmacy Key Performance Indicators Using a Modified Delphi Consensus Approach

5:15-5:45P

3

Structure-Based Identification of ATP13A3 Inhibitors Targeting Polyamine Transport in Pancreatic Ductal Adenocarcinoma

5:45-6:15P

gedatolisib Plus fulvestrant, With & Without palbociclib, vs fulvestrant in Patients With HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer: First Results From VIKTORIA-1

5:15-5:45P

4

gedatolisib, a Multitarget PI3K/AKT/mTOR Inhibitor, Plus fulvestrant With or Without palbociclib for Second-Line Treatment of Patients With HR+/HER2-/PIK3CA-WT Advanced Breast Cancer: Updated Results From the Randomized, Phase 3 VIKTORIA-1

5:45-6:15P

Autologous Stem Cell Transplantation Upfront for Multiple Myeloma vs Delayed at First Relapse

5:15-5:45P

5

Drug Monitoring in Community Oncology: Smart Monitoring and Backup Power for Safety and Savings

5:45-6:15P

Outcomes During Bruton Tyrosine Kinase Inhibitor Treatment for Chronic Lymphocytic Leukemia: Insights From Remote Therapeutic Monitoring

5:15-5:45P

6

Treatment Patterns and Outcomes Among Patients Treated With Second-Generation Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

5:45-6:15P

Impact of a New Workflow on Production Time and Production Rate of Patient Education Sheets

5:15-5:45P

7

Repurposing of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Prostate Cancer

5:45-6:15P

Effect of bezuclastinib on the Pathobiology of Mastocytosis: Changes in Bone Marrow Mast Cells, Tryptase, and KIT p.D816V Variant Allele Frequency From the Pivotal SUMMIT Trial

5:15-5:45P

8

Efficacy and Safety Results From the Pivotal SUMMIT Trial: bezuclastinib in Adults With Non-Advanced Systemic Mastocytosis

5:45-6:15P

Cell Therapy and Bispecific Antibody Administration in Community Oncology: A Case Study-Based Implementation Roadmap

5:15-5:45P

9

Clinical Decision Support With PresisCa.AI: A Retrospective Analysis of 18 Complex Oncology Cases at Carolina Blood and Cancer Care Associates

5:45-6:15P

Population Health Impact of Long COVID: A Comprehensive Analysis of Symptom Burden, Healthcare Utilization, and Demographic Disparities

5:15-5:45P

10

ibrutinib in the Management of Chronic Lymphocytic Leukemia With Leptomeningeal Involvement: Case Study and Literature Review

5:45-6:15P

Safety Event-Driven Standardization of the Cyle 1 Day 1 Nursing Chart Check to Improve Chemotherapy Readiness

5:15-5:45P

11

Weekly Safety Moments: Get the Word Out

5:45-6:15P

Engage. Educate. Elevate: Advancing Professional Development Through the Professional Educators Network

5:15-5:45P

12

Leading Locally, Collaborating Nationally: NCODA's Regional Leader Framework

5:45-6:15P